Current Antiretroviral Therapies and Future Trends in Management of Human Immunodeficiency Virus-1 Infection
Naomi S Bulteel, Clifford Leen
Erciyes Medical Journal · 2019
doi:10.14744/etd.2019.19210 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Earlier initiation of antiretroviral therapy (ART) for human immunodeficiency virus (HIV)-1 infection is associated with reduced HIV-related morbidity and mortality, improved immune recovery, and reduced risk of HIV-1 transmission. Consequently, international guidelines now recommend ART for all HIV-1-infected adults, regardless of CD4 cell count. The shift in guidance has led to concern regarding long-term ART toxicity, and new strategies to limit ART exposure have been proposed. In this review, we will discuss current recommendations for ART and future trends in management including mono- and dual-therapy, new ART formulations, and novel antiretroviral agents.
Abstract licence: CC BY-NC
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.